💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for CytRx Corporation (CYTR)
« Back to company indexCYTR Chatter Timeline
Stock Ticker for CYTR
Most Active Tweeters for CYTR
| User | Tweets |
|---|---|
| @equity_newswire | 1 |
| @SwingTradeOTC | 1 |
| @StockNewsBot2 | 1 |
| @FlashAlert_me | 1 |
| @gcassidy718 | 1 |
Recent Tweets for CYTR
 |
@equity_newswire $CYTR CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas… https://t.co/gM9hX2TsQ5 November 30th 2021, 7:11pm |
 |
@ScryingBiotech $CYTR Few, if any, seem to appreciate what Steven Kriegsman is doing by soliciting a $100m investment from the stat… https://t.co/0WosfAtblE November 30th 2021, 4:11pm |
 |
@MarcJacksonLA $CYTR CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas… https://t.co/5KfkcFk8QA November 30th 2021, 2:11pm |
 |
@gcassidy718 $CYTR CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas… https://t.co/feJqwL1IPB November 30th 2021, 1:11pm |
 |
@FlashAlert_me $CYTR [15s. delayed]: Issued Press Release on November 30, 08:00:00: CytRx Provides a Bold Vision on Centurion BioP… https://t.co/Y6GiQ41nco November 30th 2021, 1:11pm |
 |
@StockNewsBot2 $CYTR CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas… https://t.co/DbTsEBePsq November 30th 2021, 1:11pm |
 |
@SwingTradeOTC 50 DMA Support today: $CYTR $SLSDF ... https://t.co/bgMRTv9uGm November 26th 2021, 7:11pm |
 |
@nanneae The reported earnings of $CYTR in recent quarters seem unreasonable. The discretionary accruals are very high. Thes… https://t.co/Z9r2MzLRTF November 24th 2021, 5:11am |
|
@tweepygroup $CYTR $IBRX lol, he is a CONMAN, he stole Abraxane from Neil Desai and Aldox from Felix Kratz. Steve Kman is an acc… https://t.co/qsZDLjj9va November 16th 2021, 2:11am |
|
@equity_newswire $CYTR CytRx Comments on Quarterly Results and Recent Strategic Initiatives https://t.co/XbMr6u9Om7 November 12th 2021, 10:11pm |
|
@gcassidy718 $CYTR CytRx Comments on Quarterly Results and Recent Strategic Initiatives https://t.co/bQDLVdN2yD November 12th 2021, 3:11pm |
 |
@otcdynamics $CYTR CytRx Comments on Quarterly Results and Recent Strategic Initiatives https://t.co/F2AjmeZTtP November 12th 2021, 1:11pm |
|
@equity_newswire $CYTR CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in… https://t.co/FmPsj3H7U8 November 10th 2021, 5:11am |
|
@MarcJacksonLA $CYTR CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in… https://t.co/TU8Wel6Gjd November 9th 2021, 9:11pm |
|
@gcassidy718 $CYTR CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in… https://t.co/V2tSFJlVlW November 9th 2021, 9:11pm |
 |
@otc_watch_news $CYTR #OTCQB CytRx Corp. (CYTR: OTCQB) | CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for… https://t.co/BrdRB4BrXW November 9th 2021, 1:11pm |
|
@FlashAlert_me $CYTR [15s. delayed]: Issued Press Release on November 09, 08:00:00: CytRx Announces Centurion BioPharma Has Been I… https://t.co/32cY30w8XR November 9th 2021, 1:11pm |
|
@StockNewsBot2 $CYTR CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in… https://t.co/VdRTe7OOZt November 9th 2021, 1:11pm |
 |
@elephants_never @jimcramer will Patrick Soon Shiong be Vindicated a second time? with $CYTR's Aldoxorubicin https://t.co/WIg1V5eDWP @Forbes November 8th 2021, 9:11am |
 |
@MarcusDayT took a starter $CYTR - moving on almost no volume, almost maxed s/s and last vote for an a/s raise didn't have enou… https://t.co/vRdkFBTNsx November 5th 2021, 3:11pm |
|
@SwingTradeOTC 50 DMA Support today: $CYTR $BKLLF ... https://t.co/bgMRTv9uGm November 4th 2021, 7:11pm |
 |
@ontrack9_oktogo RT @elephants_never: whoever wrote this New Yorker article left out a shit ton of truth as $CYTR s Aldoxorubicin was shelved to hid it from… November 4th 2021, 3:11pm |
|
@elephants_never @DrPatSoonShiong deal with $cytr for cancer drug Aldoxorubicin is like the @Lakers buying player Kobe Bryant contra… https://t.co/I3FQWFOBAE November 4th 2021, 11:11am |
|
@equity_newswire $CYTR CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Dise… https://t.co/fbcvgqt9pN November 3rd 2021, 5:11am |
 |
@pablodesaavedra RT @gcassidy718: $CYTR CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Typ… November 3rd 2021, 4:11am |
|
@gcassidy718 $CYTR CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Dise… https://t.co/2WzyiNVC5g November 2nd 2021, 4:11pm |
|
@otc_watch_news $CYTR #OTCQB CytRx Corp. (CYTR: OTCQB) | CytRx Highlights Orphazyme’s Update on Productive Meeting with FDA Regardi… https://t.co/O35tgoF2y5 November 2nd 2021, 12:11pm |
 |
@DEUSVULTREV68 RT @mikalche: $CYTR $ORPH CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease… November 2nd 2021, 12:11pm |
 |
@63_hyacinth CytRx comments on Orphazyme Type A meeting with FDA on arimoclomol $CYTR $ORPH November 2nd 2021, 12:11pm |
 |
@James__BondOO7 RT @stock_titan: $CYTR $ORPH CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disea… November 2nd 2021, 12:11pm |
 |
@mikalche $CYTR $ORPH CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C November 2nd 2021, 12:11pm |
|
@StockNewsBot2 $CYTR $ORPH CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pic… https://t.co/PfelQwcsNp November 2nd 2021, 12:11pm |
 |
@stock_titan $CYTR $ORPH CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pic… https://t.co/Ac15P34TXN November 2nd 2021, 12:11pm |
 |
@letitride1012 RT @elephants_never: $cytr john caloz criminal scum CytRx also issued 8,240 shares of Series C 10.00% Convertible Preferred Stock (the “Pr… October 29th 2021, 3:10pm |
|
@letitride1012 RT @elephants_never: @DrPatSoonShiong did you or did you not make a shady deal with $CYTR Aldoxorubicin in order to protect Abraxane in a n… October 29th 2021, 3:10pm |
|
@elephants_never $cytr john caloz criminal scum CytRx also issued 8,240 shares of Series C 10.00% Convertible Preferred Stock (the… https://t.co/jVq10AiHFC October 29th 2021, 12:10am |
|
@elephants_never $cytr John Caloz strikes again! $8,240,000 relating to the Preferred Stock paid pursuant to the Agreement (subject… https://t.co/7bNGXOlHhy October 27th 2021, 8:10pm |
|
@elephants_never @DrPatSoonShiong did you or did you not make a shady deal with $CYTR Aldoxorubicin in order to protect Abraxane in… https://t.co/XFrDqdO2l3 October 27th 2021, 2:10am |
|
@elephants_never whoever wrote this New Yorker article left out a shit ton of truth as $CYTR s Aldoxorubicin was shelved to hid it f… https://t.co/Msbt7Ii6Gi October 26th 2021, 6:10pm |
|
@elephants_never Guy has a way of stealing drugs from companies like Altor Biosciences ( ALT 803) Cher's drug now Anktiva and $CYTR'… https://t.co/fAAqLqp4sm October 26th 2021, 6:10pm |
|
@comando52336640 @mongollidtrade Still on this one - with a side of $CYTR just for fun October 26th 2021, 5:10pm |
 |
@Utt8i The average discretionary accruals (AD) of $CYTR in recent quarters is higher than 94% of other firms in the indust… https://t.co/aq90CvFLLi October 24th 2021, 9:10am |
|
@SwingTradeOTC 20 DMA Support today: $CYTR ... https://t.co/wA0f88cC12 October 21st 2021, 6:10pm |
 |
@gaporon888 $CYTR Real price will come out soon; Follow price targets "" https://t.co/jBYUPkgCW3 October 17th 2021, 6:10pm |
 |
@marissa_crew $CYTR i am watching you October 15th 2021, 1:10pm |
 |
@YuZhu4 RT @MaisaCorp: $CYTR mature data is released in Q1 2022, ahead of ImmunityBio's $IBRX plans to meet with the U.S. Food and Drug Administrat… October 14th 2021, 11:10pm |
 |
@MaisaCorp $CYTR mature data is released in Q1 2022, ahead of ImmunityBio's $IBRX plans to meet with the U.S. Food and Drug Ad… https://t.co/zX26yMgo2U October 14th 2021, 10:10pm |
|
@MaisaCorp $IBRX CytRx $CYTR Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancrea… https://t.co/XoJZSqzOat October 14th 2021, 10:10pm |
 |
@MarketWN JUST IN: $CYTR CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Panc… https://t.co/WNZqiqo8CZ October 14th 2021, 8:10pm |
|
@equity_newswire $CYTR CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Ca… https://t.co/EK32PfYEMY October 14th 2021, 6:10pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?